Leslie Recio PhD DABT is the Chief Scientific Officer at Scitovation. Prior to Scitivoation, Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS. Dr. Recio obtained his B.S. in Microbiology and M.S. and Ph.D. in Toxicology from the University of Kentucky and has been Diplomat of the American Board of Toxicology (DABT) since 1998. Dr Recio is internationally recognized for his expertise in regulatory genetic toxicology, research in genetic and molecular toxicology and mode-of-action assessment using genomic technologies. He has served on the OECD Genetic Toxicology Expert Working Group since 2014. Dr. Recio was the PI for the National Toxicology Program (NTP) genetic toxicology testing more than for 17 yrs. In this role, Dr. Recio oversaw genotoxicity assessments of NTP test compounds in a battery of genetic toxicology assays following international regulatory testing guidelines. Dr. Recio has over 30 years of experience in toxicology research in the areas of mutagenesis, toxicogenomics, and regulatory genotoxicity assessments. His research program has included studies using primary and immortalized rodent and human cell lines, transgenic rodent models, and molecular genetic approaches to examine mechanisms and identify biomarkers of cytotoxicity, genotoxicity, and mutagenicity at the molecular, cellular, and animal level. His research program has focused on mode-of-action and the development of data useful for benchmark dose analysis to derive point of departure estimates used in risk assessments. More recently Dr. Recio has been committed to developing New Approach Methods to replace or reduce the reliance on animal testing by developing genotoxicity assessments in human hepatocyte models. In a collaboration with MIT (Bevin Engelward) and U of Ottawa (Carole Yauk), he has developed a human-relevant genotoxicity testing platform using metabolically competent human hepatocytes integrated with rapid detection of genotoxicity and mode-of-action based genomic profiling. Dr. Recio was appointed to the editorial boards of Mutagenesis, Toxicological Sciences and Mutation Research Reviews. He was appointed as an Associate Editor forToxicological Sciences from 2016-2019. He is a member of several scientific societies, including the Environmental Mutagen Society, the Society of Toxicology, and the Genetics and Environmental Mutagenesis Society, and has served several elected leadership positions, including GEMS President, President of the SOT Hispanic Organization of Toxicologists special interest group, and Council Member for the North Carolina Chapter of the Society of Toxicology.
Current role
EVP, Research & Development & Chief Scientific Officer at AbbVie
Chief Scientific Officer at Rhythm AI
President Of Research & Development And Chief Scientific Officer at Karuna Therapeutics
Chief Scientific Officer at Calico
Chief Scientific Officer at Zephyr AI
Access the worlds's biggest network of public org charts
Learn more